

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Atlas Venture Fund IX, L.P.</u> (Last) (First) (Middle) <u>25 FIRST STREET, SUITE 303</u> (Street) <u>CAMBRIDGE MA 02141</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Unum Therapeutics Inc. [UMRX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>04/03/2018</u>	
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	04/03/2018		C		3,184,446	A	(1)	3,184,446	D ⁽²⁾	
Common Stock	04/03/2018		C		83,037	A	(1)	3,267,483	D ⁽²⁾	
Common Stock	04/03/2018		P		94,052	A	\$12	3,361,535	D ⁽²⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Preferred Stock	(1)	04/03/2018		C		3,184,446		(1)	(1)	Common Stock	3,184,446	\$0.00	0	D ⁽²⁾	
Series B Preferred Stock	(1)	04/03/2018		C		83,037		(1)	(1)	Common Stock	83,037	\$0.00	0	D ⁽²⁾	

1. Name and Address of Reporting Person*
Atlas Venture Fund IX, L.P.

 (Last) (First) (Middle)
25 FIRST STREET, SUITE 303

 (Street)
CAMBRIDGE MA 02141

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Atlas Venture Associates IX, L.P.

 (Last) (First) (Middle)
25 FIRST STREET, SUITE 303

 (Street)
CAMBRIDGE MA 02141

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Atlas Venture Associates IX, LLC

 (Last) (First) (Middle)
25 FIRST STREET, SUITE 303

 (City) (State) (Zip)

(Street)

CAMBRIDGE MA 02141

(City)

(State)

(Zip)

Explanation of Responses:

1. Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date.
2. The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any.

Remarks:

Atlas Venture Fund IX, LP, By:
Atlas Venture Associates IX, LP,
its general partner, By: Atlas
Venture Associates IX, LLC, its 04/03/2018
general partner, By: Frank
Castellucci, General Counsel /s/
Frank Castellucci

Atlas Venture Associates IX, LP,
By: Atlas Venture Associates
IX, LLC, its general partner, By: 04/03/2018
Frank Castellucci, General
Counsel /s/ Frank Castellucci

Atlas Venture Associates IX,
LLC, By: Frank Castellucci,
General Counsel /s/ Frank 04/03/2018
Castellucci

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.